Back Back
Tx Selection and Optimization in MCL

CME

Treatment Selection and Optimization in MCL From a European Union Perspective

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Released: April 15, 2025

Expiration: October 14, 2025

Mats Jerkeman
Mats Jerkeman, MD, PhD
CME/CE Information

Activity

Progress
1 2
Course Completed

Overall Conclusions

In summary, there is no approved drug that is administered with a curative intent in MCL. However, the treatment outcome for patients with MCL has improved considerably over the last 20 years and the treatment landscape continues to evolve. Even though the treatment landscape has been impacted by several major therapeutic improvements with the evolution and integration of novel drug classes, immunochemotherapy remains the backbone of first-line therapy in the EU. With the introduction and incorporation of anti-CD20 antibodies (rituximab and obinutuzumab), covalent BTK inhibitors, noncovalent BTK inhibitors, and CAR T-cell therapies, the prognosis for many patients with MCL has significantly improved.

It seems likely that in the near future, covalent BTK inhibitors will move into the first-line setting, either alone or in combination with a BCL2 inhibitor or immunochemotherapy. The treatment of patients with R/R disease remains a clinical challenge, especially because patients experience a decreasing duration of response after each relapse. After disease progression on a BTK inhibitor–based treatment, the prognosis for patients becomes particularly unfavorable.

Currently, CAR T-cell therapy and pirtobrutinib have important roles in the management of patients in the R/R setting, especially after progression on a covalent BTK inhibitor. It is my hope that glofitamab will soon emerge with an indication for patients with R/R MCL, and possibly become an option in the frontline setting. In conclusion, the management of patients with MCL has a bright future with several promising agents and combinations on the horizon.

BACK | NEXT